Orbital Cellulitis

Orbital cellulitis is a sight- and life-threatening infection of the soft tissues posterior to the orbital septum, most commonly arising from contiguous spread of paranasal sinusitis (especially ethmoid). It is classified using the Chandler staging system: Stage I (preseptal cellulitis), Stage II (orbital cellulitis), Stage III (subperiosteal abscess), Stage IV (orbital abscess), Stage V (cavernous sinus thrombosis). [1] All confirmed cases require hospitalization, IV antibiotics, and emergent ophthalmology consultation. [2-3]

• Onset and progression: Acute onset of periorbital swelling, pain, and redness — ask about rapidity of progression (hours vs. days)
• Preceding illness: Recent or concurrent sinusitis (present in ~78–100% of orbital cellulitis cases), URI symptoms, nasal congestion, purulent rhinorrhea [4-5]
• Trauma/procedures: Periorbital trauma, insect bites, dental infections, recent dental or sinus surgery, ORIF of facial fractures [6]
• Visual symptoms: Blurred vision, diplopia, decreased acuity — critical to document timing and severity [2]
• Pain characterization: Deep orbital pain, pain with eye movement (distinguishes from preseptal), headache [2][7]
• Systemic symptoms: Fever, malaise, nausea/vomiting (vomiting may suggest intracranial extension) [8]
• Important negatives: No history of immunosuppression, no poorly controlled diabetes (raises concern for mucormycosis) [2]

• Decreased visual acuity or relative afferent pupillary defect (RAPD) — suggests optic neuropathy or orbital compartment syndrome [2][9]
• Complete ophthalmoplegia — suggests severe postseptal disease or cavernous sinus thrombosis [1]
• Bilateral periorbital involvement — raises concern for cavernous sinus thrombosis [10]
• Altered mental status, severe headache, or meningismus — suggests intracranial extension (meningitis, epidural/subdural abscess, brain abscess) [8]
• Elevated IOP (>20 mmHg) or severe proptosis (>5 mm) — indications for urgent surgical intervention [8]
• Failure to improve within 24–48 hours on IV antibiotics [8]
• Black eschar on nasal turbinates or palate in a diabetic or immunocompromised patient — mucormycosis until proven otherwise [2]

Empiric IV Antibiotics (inpatient)

• Vancomycin (MRSA/resistant pneumococcus coverage) PLUS a broad-spectrum agent:
  • Ceftriaxone, ampicillin-sulbactam, or piperacillin-tazobactam [8]
  • Add metronidazole if using ceftriaxone (for anaerobic coverage, especially with sinogenic source or intracranial complications) [8]
• Standard dosing: Vancomycin 1 g IV BID (adults) or 40 mg/kg/day divided BID (pediatric); Ceftriaxone 1 g IV BID (adults) or 100 mg/kg/day divided BID (pediatric) [1]

Adjunctive

• Corticosteroids: Controversial; some evidence supports adjuvant oral prednisolone (1.5 mg/kg/day) starting day 4–7 after initial antibiotic response, tapered over 1–2 weeks — may reduce hospital stay and edema. A Cochrane review found insufficient evidence to make definitive recommendations [1][5]
• Topical antibiotics and lubricants for corneal protection [1]

Contraindicated/Cautions

• Avoid oral-only antibiotics for confirmed orbital cellulitis — IV therapy is mandatory [2]
• Avoid steroids if fungal infection is suspected [1]

IV-to-oral transition: When clear clinical and laboratory improvement is observed; total duration approximately 2–3 weeks [11]

• No specific dietary triggers or restrictions
• Ensure adequate hydration, especially in febrile patients
• NPO if surgical intervention is anticipated

• HEENT: Nasal congestion, purulent rhinorrhea, facial pain/pressure, dental pain, anosmia
• Ophthalmologic: Vision changes, diplopia, eye pain, tearing, discharge
• Neurologic: Headache (especially frontal), altered mental status, neck stiffness, photophobia
• Constitutional: Fever, chills, rigors, fatigue
• Dental: Recent toothache, dental procedures, jaw swelling

• Vaccination history: Pneumococcal and H. influenzae type b vaccination status (post-vaccine era has shifted microbiology toward Staphylococcal predominance) [1][7]
• Immunocompromised state: HIV, chemotherapy, organ transplant, chronic steroid use — raises concern for fungal etiology
• Diabetes mellitus: Poorly controlled diabetes is a major risk factor for invasive fungal sinusitis (mucormycosis) [2][9]
• Prior episodes of sinusitis or periorbital infections
• Family history is generally not contributory

• Sinusitis (most common predisposing factor, especially ethmoid sinusitis) [4][6]
• Pediatric age group (more common in children; peak incidence ages 0–19) [6][9]
• Male sex (slight predominance, especially for intracranial complications in adolescents) [8]
• Periorbital/facial trauma, insect bites, skin abrasions [7]
• Dental infections or recent dental procedures [6]
• Prior orbital/sinus surgery, ORIF of facial fractures [6]
• Immunosuppression and poorly controlled diabetes (risk for fungal orbital cellulitis) [2]
• Chronic sinusitis [9]

• Preseptal (periorbital) cellulitis — eyelid swelling/erythema WITHOUT proptosis, ophthalmoplegia, or pain with eye movement; CRP typically much lower [5]
• Orbital compartment syndrome — acute proptosis, elevated IOP, vision loss; may coexist with orbital cellulitis; requires emergent lateral canthotomy [3]
• Orbital inflammatory pseudotumor (idiopathic orbital inflammation) — painful ophthalmoplegia, proptosis; typically no fever; imaging may overlap [12]
• Orbital/periorbital tumor (rhabdomyosarcoma in children, lymphoma in adults) — subacute course, less inflammatory
• Cavernous sinus thrombosis — bilateral eye findings, cranial nerve palsies (III, IV, V1, V2, VI), altered mental status [10]
• Dacryocystitis/dacryoadenitis — localized swelling at medial canthus or lacrimal gland
• Invasive fungal sinusitis (mucormycosis/aspergillosis) — immunocompromised or diabetic patients, black eschar, rapidly progressive [2]
• Thyroid eye disease (Graves' orbitopathy) — bilateral proptosis, lid retraction, no fever
• Allergic reaction/angioedema — bilateral, non-tender, no fever

• Prior sinusitis episodes (acute or chronic)
• Previous periorbital or orbital infections
• History of sinus or orbital surgery
• Dental disease or recent procedures
• Diabetes mellitus (type and control)
• Immunosuppressive conditions or medications
• Vaccination history (PCV, Hib)

Vital Signs

• Fever (present in ~82% of orbital cellulitis vs. ~52% of preseptal) [5]
• Tachycardia; assess for sepsis

Eye Exam (critical — perform before swelling prevents assessment):

• Eyelid edema and erythema — may be severe enough to prevent eye opening
• Proptosis — present in ~55% of orbital cellulitis; measure with Hertel exophthalmometer if available [4]
• Chemosis (conjunctival edema/injection) [2]
• Restricted/painful extraocular movements — hallmark distinguishing feature from preseptal cellulitis [5][7]
• Visual acuity — document baseline; decreased acuity is an emergency
• Pupillary exam — check for RAPD (afferent pupillary defect suggests optic nerve compromise) [9]
• Intraocular pressure — elevated IOP (>20 mmHg) suggests orbital compartment syndrome [8]
• Fundoscopy — look for papilledema, retinal vein engorgement

Other

• Anterior rhinoscopy — purulent drainage, mucosal edema, black eschar (mucormycosis)
• Dental exam — periapical abscess, facial swelling
• Cranial nerve exam — CN III, IV, V1/V2, VI deficits suggest cavernous sinus involvement [10]
• Mental status assessment

• CBC with differential: Leukocytosis (significantly higher in orbital vs. preseptal cellulitis) [4]
• CRP: Markedly elevated; CRP >120 mg/L has been proposed as a cutoff suggesting orbital (vs. preseptal) involvement [5][13]
• Blood cultures: Obtain before starting antibiotics (low yield but important if positive)
• Wound/abscess cultures: Culture any purulent drainage or tissue obtained surgically — optimal diagnostic specimen [2]
• Procalcitonin: May help assess severity of bacterial infection
• BMP/metabolic panel: Assess renal function (for vancomycin dosing), glucose (screen for diabetes)
• ESR: Nonspecific but may be elevated

First-line

• CT orbits and sinuses with IV contrast — critical for all suspected orbital cellulitis [3][12]
  • Differentiates preseptal from postseptal disease
  • Identifies subperiosteal or orbital abscess (medial subperiosteal abscess is most common, ~59%) [5]
  • Evaluates paranasal sinus opacification and bony erosion
  • Detects superior ophthalmic vein thrombosis [12]

When CT is non-diagnostic or intracranial extension suspected:

• MRI brain and orbits with and without contrast[3][14]

Adjunctive

• Point-of-care ultrasound (POCUS)cannot exclude intracranial extension[3]

When imaging is unnecessary

• [8]

Chandler Classification (staging system for severity): [1]

• Stage I: Preseptal cellulitis
• Stage II: Orbital cellulitis (postseptal, diffuse)
• Stage III: Subperiosteal abscess
• Stage IV: Orbital abscess
• Stage V: Cavernous sinus thrombosis

Other

• POCUS: Bedside assessment for proptosis, retrobulbar fluid collection
• Tonometry: IOP measurement if orbital compartment syndrome suspected
• Nasal endoscopy (by ENT): Evaluate sinus drainage pathways, obtain cultures, rule out fungal disease
• KOH prep / fungal stains on tissue if mucormycosis suspected

• Not routinely indicated unless sepsis is present or the patient has cardiac comorbidities
• Consider if planning prolonged IV antibiotic therapy with QT-prolonging agents (e.g., fluoroquinolones)

Orbital cellulitis is an ophthalmologic emergency with potential for permanent vision loss, intracranial infection, and death. [2][7] The most common etiology is contiguous spread from ethmoid sinusitis. Key pathogens include Staphylococcus aureus (including MRSA), Streptococcus species, H. influenzae, anaerobes, and gram-negative rods; polymicrobial infections are more common in patients >15 years. [1][6]

Severity stratification follows the Chandler classification. Complications include: [1][6]

• Subperiosteal abscess (most common complication, ~59% medial location)
• Orbital abscess
• Vision loss (via optic neuropathy, CRAO, exposure keratopathy)
• Cavernous sinus thrombosis
• Intracranial extension (meningitis, epidural/subdural abscess, brain abscess)
• Osteomyelitis (Pott's puffy tumor with frontal sinusitis)

Initial Stabilization

• Assess for orbital compartment syndrome — if present, perform emergent lateral canthotomy and cantholysis [3]
• Secure IV access; initiate fluid resuscitation if septic

Empiric IV Antibiotics (start immediately)

• Vancomycin + ceftriaxone (± metronidazole for anaerobic coverage) [8]
• OR Vancomycin + ampicillin-sulbactam [8]
• OR Vancomycin + piperacillin-tazobactam [8]
• Tailor based on culture results when available

Surgical Indications: [2][8]

• Large subperiosteal or orbital abscess
• Failure to improve within 24–48 hours on IV antibiotics
• Impaired visual acuity or RAPD
• Complete ophthalmoplegia
• Elevated IOP >20 mmHg
• Severe proptosis >5 mm
• Intracranial extension
• Suspected invasive fungal infection

Small abscesses with minimal ocular/neurologic findings may be trialed with IV antibiotics for 24–48 hours with frequent visual checks before deciding on surgery. [8]

Adjunctive steroids: May be considered after 3–7 days of antibiotic response (prednisolone 1.5 mg/kg/day, tapered over 1–2 weeks); evidence remains limited. [1]

IV-to-oral transition: After clear clinical improvement; complete approximately 2–3 weeks total antibiotic therapy. [11]

All confirmed orbital cellulitis requires hospital admission. [2-3]

Admission criteria

• Any postseptal findings (proptosis, ophthalmoplegia, pain with eye movement, decreased visual acuity)
• Preseptal cellulitis with eyelid >50% closed, systemic toxicity, or failure of outpatient antibiotics [8]
• Any abscess on imaging

Consultation triggers

• Ophthalmology: All cases [2]
• ENT/Otolaryngology: Sinogenic source, need for sinus drainage [2]
• Neurosurgery: Intracranial extension (epidural/subdural abscess, brain abscess, cavernous sinus thrombosis) [3]
• Infectious disease: Complex or refractory cases, immunocompromised patients [2]

Discharge criteria

• Afebrile for ≥24–48 hours
• Improving proptosis, extraocular motility, and visual acuity
• Tolerating oral antibiotics
• Declining inflammatory markers
• Reliable follow-up arranged

Follow-up timing

• Ophthalmology follow-up within 1 week of discharge
• ENT follow-up if sinogenic source for ongoing sinus management
• Primary care follow-up within 1–2 weeks

Return precautions — instruct patients/families to return immediately for:

• Worsening or new vision changes (blurring, double vision, vision loss)
• Increasing eye swelling, redness, or pain
• New-onset severe headache, neck stiffness, or confusion
• Recurrence of fever
• Nausea/vomiting

Expected recovery

• Clinical improvement typically begins within 24–48 hours of IV antibiotics [8]
• Complete resolution of edema and erythema may take 1–2 weeks
• Average hospital stay is approximately 4–6 days (longer with surgical intervention) [9][15]
• Permanent vision loss occurs in approximately 0.6% and intracranial complications in ~1.6% of hospitalized children [13]

1. Corticosteroids for Periorbital and Orbital Cellulitis. — Kornelsen E, Mahant S, Parkin P, et al. The Cochrane Database of Systematic Reviews. 2021.

2. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.

3. High Risk and Low Prevalence Diseases: Orbital Cellulitis. — Pelletier J, Koyfman A, Long B. The American Journal of Emergency Medicine. 2023.

4. Pediatric Preseptal and Orbital Cellulitis: A Comparative Study of Clinical, Radiologic, and Laboratory Features. — Şahin A, Tanriverdi Kaymaz C, Kara Aksay A, et al. The Pediatric Infectious Disease Journal. 2025.

5. Preseptal Versus Orbital Cellulitis in Children: An Observational Study. — Miranda-Barrios J, Bravo-Queipo-de-Llano B, Baquero-Artigao F, et al. The Pediatric Infectious Disease Journal. 2021.

6. Bacterial Orbital Cellulitis - A Review. — Yadalla D, Jayagayathri R, Padmanaban K, et al. Indian Journal of Ophthalmology. 2023.

7. Wilderness Medical Society Clinical Practice Guidelines for Treatment of Eye Injuries and Illnesses in the Wilderness: 2024 Update. — Paterson R, Drake B, Tabin G, Cushing T. Wilderness & Environmental Medicine. 2024.

8. Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years. — Wald ER, Applegate KE, Bordley C, et al. Pediatrics. 2013.

9. Orbital Complications of Paranasal Sinusitis in Taiwan, 1988 Through 2015: Acute Ophthalmological Manifestations, Diagnosis, and Management. — Chang YS, Chen PL, Hung JH, et al. PloS One. 2017.

10. Septic Cavernous Sinus Thrombosis Associated With Orbital Cellulitis: A Report of 6 Cases and Review of Literature. — Branson SV, McClintic E, Yeatts RP. Ophthalmic Plastic and Reconstructive Surgery. 2018.

11. Applying Pharmacodynamics and Antimicrobial Stewardship to Pediatric Preseptal and Orbital Cellulitis. — Stimes GT, Girotto JE. Paediatric Drugs. 2019.

12. ACR Appropriateness Criteria® Vision Loss. — Expert Panel on Neurological Imaging, Friedman ER, Juliano AF, et al. Journal of the American College of Radiology : JACR. 2025.

13. Factors Associated With Surgery and Imaging Characteristics in Severe Orbital Infections. — Gill PJ, Drouin O, Pound C, et al. The Journal of Pediatrics. 2022.

14. Imaging of Painful Ophthalmologic Disorders. — Winegar BA. Neurologic Clinics. 2022.

15. Association of Empiric Antibiotic Selection and Clinical Outcomes in Hospitalised Children With Severe Orbital Infections: A Retrospective Cohort Study. — Krueger C, Nguyen EL, Mahant S, et al. Archives of Disease in Childhood. 2024.